Overview:
The Arthritis Foundation defines psoriatic arthritis as an autoimmune inflammatory disease which primarily affects the skin. Majorly 30% of the patients suffering with psoriasis develop psoriatic arthritis during the later stages of the disease. Psoriatic arthritis affects men and women equally with the global prevalence rate of 6 per 100,000 people. It is a heterogeneous disease and categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans. The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and recent development of interleukin-17 inhibitors. The occurrence is high in the Caucasian populations of North America and Europe followed by Asia Pacific.
According to the International Federation of Psoriasis Associations (IFPA) 2016 statistics, around 125 million people throughout the globe are suffering with psoriatic arthritis. The diagnosis of psoriatic arthritis is complex due to the presence of symptoms in patients such as tendinitis, inflammatory spinal pain, or dactylitis, which are most often misunderstood as arthritis. Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease such as mild, moderate, or severe psoriatic arthritis. The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab and brodalumab have a better drug safety and efficacy for the treatment of psoriatic arthritis. ABT-494 (Abbvie, Inc.) and Aprelimast (Celgene Corporation) and Certolizumab Pegol (UCB BIOSCIENCES GmbH) are being developed as targeted therapies and are set to launch during the forecast period from 2018 to 2026 and capitalize the psoriatic arthritis treatment market.
The psoriatic arthritis treatment market is segmented on the following bases:
- Mechanism of Action
- TNF Inhibitors
- PDE4 Inhibitors
- Interleukin Blockers
- Others
- Geography
- North America
- Europe
- United Kingdom
- Germany
- Rest of Europe
- Asia Pacific
- Japan
- China
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
Key players identified for psoriatic arthritis treatment market includes:
Abbvie, Inc., Amgen, Inc., Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F.Hoffman La-Roche AG, Janssen Global Services, Merck & Co., Novartis AG, Valeant Pharmaceuticals International, Inc.
This report offers:
- For the scope of this report, 2017 is considered as the base year with forecast period from 2018 to 2026, the market size data and compound annual growth rate is given in the market assessment studies
- The attractive investment proposition are given for the mechanism of action and geography segment to understand the business strategy of the key players in psoriatic arthritis market
- Emerging biosimilars market which are an alternative for the biologic drugs employed for the treatment of psoriatic arthritis has created a competitive environment among the key players
- Company profiles segment provides the diverse drugs available for the treatment of psoriatic arthritis in the product portfolio segment.
- The information regarding the latest growth strategies of the competitors are comprehensively covered in the key developments sections
